Robert Roberts
Cardiovascular Disease · Phoenix, AZNPI 1518406982
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Cumberland Pharmaceuticals, Inc. accounts for 66.2% of it on its own, with 21 other manufacturers making up the rest.
Across 81 payments — averaging $107.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cumberland Pharmaceuticals, Inc.$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$541
- Boehringer Ingelheim$352
- Amgen$346
- AstraZeneca$301
- Abbott$214
- plus $1K from 16 others
What the payments were for
- Consulting fees$4,00046%
- Travel & lodging$1,76720%
- Food & beverage$2,93334%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cumberland Pharmaceuticals, Inc. | 6 | $5,767 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $541 |
| Boehringer Ingelheim | 11 | $352 |
| Amgen | 5 | $346 |
| AstraZeneca | 5 | $301 |
| Abbott | 5 | $214 |
| Amarin Pharma, Inc. | 2 | $152 |
| Novo Nordisk | 2 | $149 |
| Medtronic | 1 | $147 |
| E.r. Squibb & Sons, L.L.C. | 2 | $135 |
| Regeneron | 1 | $113 |
| Philips North America LLC | 4 | $95 |
| Kestra Medical Technology Services, Inc. | 4 | $81 |
| ZOLL Respicardia, Inc. | 4 | $68 |
| Novartis | 3 | $64 |
| Johnson & Johnson | 3 | $59 |
| Irhythm Technologies, Inc. | 2 | $35 |
| Cvrx, Inc. | 1 | $25 |
| Itamar Medical Inc | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Lemaitre Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kristalose$2,000
- SANCUSO$2,000
- Vaprisol Dextrose in Plastic Container$2,000
- Caldolor$2,000
- Vibativ$2,000
- Repatha$244
- LifeVest$156
- CoreValve Evolut$147
- FARXIGA$126
- Ozempic$124
- RYBELSUS$124
- CAMZYOS$122
- QUADRA ASSURA$115
- Vascepa$113
- DUPIXENT$113
- JARDIANCE$105
How this compares
$8,709 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 14 | $327 |
| Rosuvastatin Calcium | 11 | $265 |
| Amlodipine Besylate | 63 | $242 |
| Lisinopril | 13 | $79 |
| Hydrochlorothiazide | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.